Combo therapy lowers natriuretic peptide, study shows

But the study, PARALLAX, found no benefit in a six-minute walk test, researchers say
Medicom Staff writer

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Results of a trial of sacubitril and valsartan in patients with heart failure with preserved ejection fraction (HFpEF) show a reduction in N-terminal pro-b-type natriuretic peptide ( NT-proBNP), researchers report.